These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 11151775

  • 1. [Drug therapy of ventricular tachycardia].
    Gonska BD.
    Z Kardiol; 2000; 89 Suppl 10():51-7; discussion 57-8. PubMed ID: 11151775
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W, Borggrefe M, Block M, Böcker D, Breithardt G.
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [Abstract] [Full Text] [Related]

  • 3. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.
    Am J Cardiol; 1997 Sep 11; 80(5B):3F-9F. PubMed ID: 9291444
    [Abstract] [Full Text] [Related]

  • 4. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R.
    Am J Cardiol; 1999 Mar 11; 83(5B):68D-73D. PubMed ID: 10089843
    [Abstract] [Full Text] [Related]

  • 5. [Drug therapy of ventricular arrhythmias].
    Hohnloser SH.
    Med Klin (Munich); 1997 Apr 15; 92(4):208-10. PubMed ID: 9221302
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacological therapy for ventricular arrhythmias: evidence for current treatment strategies and perspectives for the future].
    Wegener FT, Grönefeld GC, Duray G, Ehrlich JR, Hohnloser SH.
    Internist (Berl); 2006 Mar 15; 47(3):297-304, 306-7. PubMed ID: 16418866
    [Abstract] [Full Text] [Related]

  • 7. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A, Sapp J.
    Curr Cardiol Rep; 2017 Sep 13; 19(11):105. PubMed ID: 28900864
    [Abstract] [Full Text] [Related]

  • 8. [Acute treatment of stable hemodynamically tolerable ventricular tachycardia].
    Haverkamp W, Rolf S, Stockburger M, Dietz R.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2005 Apr 13; 40(4):207-12. PubMed ID: 15832239
    [Abstract] [Full Text] [Related]

  • 9. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
    Block M, Hammel D, Böcker D, Borggrefe M, Breithardt G.
    Am J Cardiol; 1996 Sep 12; 78(5A):62-8. PubMed ID: 8820838
    [Abstract] [Full Text] [Related]

  • 10. [Cardiac arrhythmias during pregnancy--what to do?].
    Trappe HJ.
    Herz; 2003 May 12; 28(3):216-26. PubMed ID: 12756479
    [Abstract] [Full Text] [Related]

  • 11. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G, Ciaccheri M, Cecchi F, Troiani V, Nannini M, Marconi P, Olivotto J, Montereggi A, Dolara A.
    G Ital Cardiol; 1999 May 12; 29(5):514-23. PubMed ID: 10367218
    [Abstract] [Full Text] [Related]

  • 12. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN, Fletcher RD.
    Am J Cardiol; 1999 Nov 04; 84(9A):103R-108R. PubMed ID: 10568668
    [Abstract] [Full Text] [Related]

  • 13. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.
    Van Herendael H, Dorian P.
    Vasc Health Risk Manag; 2010 Aug 09; 6():465-72. PubMed ID: 20730062
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
    Kochs M, Eggeling T, Hombach V.
    Eur Heart J; 1993 Sep 09; 14 Suppl E():107-19. PubMed ID: 8223747
    [Abstract] [Full Text] [Related]

  • 15. Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
    Böcker D, Breithardt G.
    Am J Cardiol; 1999 Mar 11; 83(5B):83D-87D. PubMed ID: 10089846
    [Abstract] [Full Text] [Related]

  • 16. Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone.
    Yalçinkaya S, Kumbasar SD, Semiz E, Tosun Z, Paksoy N.
    J Electrocardiol; 1997 Apr 11; 30(2):147-9. PubMed ID: 9141611
    [Abstract] [Full Text] [Related]

  • 17. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE, Bauman AL.
    Pharmacotherapy; 2001 May 11; 21(5):556-75. PubMed ID: 11349745
    [Abstract] [Full Text] [Related]

  • 18. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar 11; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

  • 19. The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death.
    Josephson ME, Callans DJ, Buxton AE.
    Ann Intern Med; 2000 Dec 05; 133(11):901-10. PubMed ID: 11103061
    [Abstract] [Full Text] [Related]

  • 20. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.
    N Engl J Med; 1997 Nov 27; 337(22):1576-83. PubMed ID: 9411221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.